Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers

PURPOSE: Evaluate the pharmacodynamics, pharmacokinetics, and safety of paltusotine, an orally bioavailable, nonpeptide, somatostatin receptor subtype 2 (SST2) agonist being developed for the treatment of acromegaly and neuroendocrine tumors. METHODS: A randomized, double-blind, placebo-controlled,...

Descripción completa

Detalles Bibliográficos
Autores principales: Madan, Ajay, Markison, Stacy, Betz, Stephen F., Krasner, Alan, Luo, Rosa, Jochelson, Theresa, Lickliter, Jason, Struthers, R. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894159/
https://www.ncbi.nlm.nih.gov/pubmed/35000098
http://dx.doi.org/10.1007/s11102-021-01201-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894159/
https://www.ncbi.nlm.nih.gov/pubmed/35000098
http://dx.doi.org/10.1007/s11102-021-01201-z

Ejemplares similares